[en] Levetiracetam (2S-(2-oxo-1-pyrrolidinyl)butanamide, KEPPRA(R)), a novel antiepileptic drug, has been shown to bind to a specific binding site located in the brain (Eur. J. Pharmacol. 286 (1995) 137). To identify the protein constituent of the levetiracetam binding site in situ, we synthesized the photoaffinity label [H-3]ucb 30889 ((2S)-2-[4-(3-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide), a levetiracetam analog with higher affinity for the levetiracetam binding site. This radioligand was used to map the levetiracetam binding site within the brain and to study its cellular and subcellular distribution. Autoradiography experiments using [H-3]ucb 30889 in rat brain revealed a unique distribution profile that did not match that of classical receptors known to be involved in the generation of epileptic seizures. There was a high level of binding in the dentate gyrus, the superior colliculus, several thalamic nuclei, the molecular layer of the cerebellum and to a lesser extent in the cerebral cortex, the striatum and the hypothalamus. The levetiracetam binding site was restricted to neuronal cell types, undifferentiated PC 12 cells and was highly enriched in synaptic vesicles. [H-3]ucb 30889 was also used in photoaffinity labelling studies and shown to bind covalently to a membrane protein with a molecular weight of approximately 90 kDa. (C) 2003 Elsevier B.V. All rights reserved.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Fuks, Bruno; UCB SA > Pharma Sector > In vitro Pharmacology
Gillard, Michel; UCB SA > Pharma Sector > In vitro Pharmacology
Michel, Philippe; UCB SA > Pharma Sector > In vitro Pharmacology
Lynch, Berkley; UCB Research Inc
Vertongen, Pascale; Université Libre de Bruxelles - ULB > Department of Biochemistry and Nutrition
Leprince, Pierre ; Université de Liège - ULiège > CNCM/ Centre fac. de rech. en neurobiologie cell. et moléc.
Klitgaard, Henrik; UCB SA > Pharma Sector > In vitro Pharmacology
Chatelain, Pierre; UCB SA > Pharma Sector > In vitro Pharmacology
Language :
English
Title :
Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines
Bailey A., Kelland E.E., Thomas A., Biggs J., Crawford D., Kitchen I., Toms N.J. Regional mapping of low-affinity kainate receptors in mouse brain using [3H](2S,4R)-4-methylglutamate autoradiography. Eur. J. Pharmacol. 431:2001;305-310.
Cans A.-S., Höö F., Shupliakov O., Ewing A.G., Eriksson P.S., Brodin L., Orwar O. Measurement of the dynamics of exocytosis and vesicle retrieval at cell populations using a quartz crystal microbalance. Anal. Chem. 73:2001;5805-5811.
Chen Y.A., Scales S.J., Duvvuri V., Murthy M., Patel S.M., Schulman H., Scheller R.H. Calcium regulation of exocytosis in PC12 cells. J. Biol. Chem. 276:2001;26680-26687.
De Souza E.B., Rule B.L., Tam S.W. [3H]Linopirdine (DuP 996) labels a novel binding site in rat brain involved in the enhancement of stimulus-induced neurotransmitter release: autoradiographic localization studies. Brain Res. 582:1992;335-341.
Gillard M., Fuks B., Michel P., Vertongen P., Massingham R., Chatelain P. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur. J. Pharmacol. 2003;. (in press).
Hawkins L.M., Beaver K.M., Jane D.E., Taylor P.M., Sunter D.C., Roberts P.J. Characterization of the pharmacology and regional distribution of (S)-[3H]-5-fluorowillardiine binding in rat brain. Br. J. Pharmacol. 116:1995;2033-2039.
Hovinga C.A. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy. 21:2001;1375-1388.
Hudtloff C., Thomssen C. Autoradiographic visualization of group III metabotropic glutamate receptors using [3H]-L-2-amino-4- phosphonobutyrate. Br. J. Pharmacol. 124:1998;971-977.
Jansen K.L., Faull R.L., Dragunow M. NMDA and kainic acid receptors have a complementary distribution to AMPA receptors in the human cerebellum. Brain Res. 532:1990;351-354.
Jarvis S.E., Zamponi G.W. Interactions between presynaptic Ca 2+ channels, cytoplasmic messengers and proteins of the synaptic vesicle release complex. Trends Pharmacol. Sci. 22:2001;519-525.
Laemmli U.K. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (Lond.). 227:1970;680-685.
Lee S.H., Valtschanoff J.G., Kharazia V.N., Weinberg R., Sheng M. Biochemical and morphological characterization of an intracellular compartment containing AMPA receptors. Neuropharmacology. 41:2001;680-692.
Leprince P., Lefebvre P.P., Rigo J.-M., Delree P., Rogister B., Moonen G. Cultured astroglia release a neuronotoxic activity that is not related to the excitotoxins. Brain Res. 502:1989;21-27.
Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 43(1):2002;9-18.
Lynch B.A., Matagne A., Klitgaard H. Levetiracetam has no measurable binding to, or observed antagonist effect at metabotropic glutamate receptors. Eur. J. Neurol. 9(Suppl. 2):2002.
Margineanu, D.G., Klitgaard, H., 2002. Levetiracetam. Mechanisms of action. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E., Antiepileptic Drugs. Lippincott, Williams and Wilkins, Philadelphia, pp. 419-427.
Mourre C., Moll C., Lombet A., Lazdunski M. Distribution of voltage-dependent Na+ channels identified by high-affinity receptors for tetrodotoxin and saxitoxin in rat and human brains: quantitative autoradiographic analysis. Brain Res. 448:1988;128-139.
Mutel V., Buchy D., Klingelschmidt A., Messer J., Bleuel Z., Kemp J.A., Richards J.G. In vitro properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J. Neurochem. 70:1998;2147-2155.
Nash E.M., Sangha K.S. Levetiracetam. Am. J. Health-Syst. Pharm. 58:2001;1195-1199.
Noyer M., Gillard M., Matagne A., Hénichart J.-P., Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286:1995;137-146.
Olsen R.W., McCabe R.T., Wamsley J.K. GABAA receptor subtypes: autoradiographic comparison of GABA, benzodiazepine, and convulsant binding sites in the rat central nervous system. J. Chem. Neuroanat. 3:1990;59-76.
Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., Leprince P., Moonen G., Selak I., Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol. 136(5):2002;659-672.
Sieghart W., Eichinger A., Richards J.G., Mohler H. Photoaffinity labelling of benzodiazepine receptor proteins with the partial inverse agonist [3H]Ro 15-4513: a biochemical and autoradiographic study. J. Neurochem. 48:1987;46-52.
Whorlow S.L., Loiacorno R.E., Angus J.A., Wright C.E. Distribution of N-type Ca2+ channel binding sites in rabbit brain following central administration of omega-conotoxin GVIA. Eur. J. Pharmacol. 315:1996;11-18.
Wong E.H.F., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. U. S. A. 83:1986;7104-7108.
